Josh Bilenker, MD
Josh Bilenker, MD, is the Chief Executive Officer of Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, and a Director at Sana Biotechnology. Josh joined Eli Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he had been founding CEO. From 2006 to 2013, Josh worked as a life sciences venture capital investor at Aisling Capital LLC. From 2004 to 2006, Josh served as a medical officer at the US Food and Drug Administration, in the Office of Oncology.
Josh trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his MD from The Johns Hopkins University School of Medicine and his AB degree in English from Princeton University.